← Home / Pfizer Inc. (PFE)
Stock Analysis
Pfizer Inc. (PFE)
PFE
PFE · Healthcare • Pharma
24.91 -0.95%
Track PFE in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when PFE price is:
52W Range Position
31%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-07-31 11:41 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Weak / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
25.10
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
18
◈
Strategic Agreement
HIGH
PFE strategic agreement
Regulation FD Disclosure Following the disclosure of Pfizer’s Chief Financial Officer transition announcement on June 18, 2026, Pfizer today is reaffirming its fiscal year 2026 guidance introduced December 16, 2025 and reaffirmed on its first quarter earnings call on May 5, 2026.
8-K Filing • SEC EDGAR
JUN
18
●
Management / Board
MEDIUM
Pfizer Announces Chief Financial Officer Transition
(NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted.
8-K Filing • SEC EDGAR
MAY
5
●
Financial Results
HIGH
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
(NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance (2) .
8-K Filing • SEC EDGAR
What's Driving PFE?
📈 Technical recovery is improving
Momentum is Neutral. Watch 25.10 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Pattern
Triangle Compression / DESC / UP
State
Forming
Downtrend Structure
Downtrend line not broken yet · score 36
Trigger
25.34
Invalidation
25.34
Compression
41%
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 23.62 and resistance around 25.11. The chart still needs to reclaim resistance to improve meaningfully, while any loss of support would keep weakness in control.
Price Chart
PFE — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-30
Value
Value-oriented setup
Sales and book multiples are contained.
Market Cap
$142.8B
Company size
EV
$148.9B
Debt-adjusted value
P/E
19.1
Reasonable
P/B
1.6
Low book multiple
P/FCF
15.1
Low multiple
FCF Yield
6.64%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Healthy
⚖
Balance Sheet
Manageable
💵 Revenue
-554.00M
↘ Weak
📈 Net Income
2.69B
↘ Negative
🧮 EPS (Basic)
0.47
↘ Negative
Pfizer Inc.
Healthcare • Pharma
Related Opportunities